2022
CAV2.3 expression is upregulated in the substantia nigra pars compacta of humans with Parkinson's disease
Sharifi P, Bae H, Gveric D, Gentleman S, Smith P, Tierney T, Alavian K. CAV2.3 expression is upregulated in the substantia nigra pars compacta of humans with Parkinson's disease. Brain Disorders 2022, 5: 100031. DOI: 10.1016/j.dscb.2022.100031.Peer-Reviewed Original Research
2019
Post mortem examination of Parkinson's disease brains suggests decline in mitochondrial biomass, reversed by deep brain stimulation of subthalamic nucleus
Mallach A, Weinert M, Arthur J, Gveric D, Tierney TS, Alavian KN. Post mortem examination of Parkinson's disease brains suggests decline in mitochondrial biomass, reversed by deep brain stimulation of subthalamic nucleus. The FASEB Journal 2019, 33: 6957-6961. PMID: 30862197, DOI: 10.1096/fj.201802628r.Peer-Reviewed Original ResearchConceptsDeep brain stimulationParkinson's disease brainSubthalamic nucleusParkinson's diseaseDisease brainBrain stimulationPresynaptic terminalsSNpc neuronsEffects of DBSLong-term clinical benefitSubstantia nigra pars compactaLate-stage patientsMitochondrial biomassDA neuronsSTN-DBSSurgical treatmentNeuroprotective effectsPars compactaClinical benefitDA projectionsPD brainsDopaminergic neuronsDBS treatmentNeuromodulatory effectsPD cases